natgillin/translations-raw huggingface dataset:
HCV ANITIVIRAL AGENTS: HCV PROTEASE INHIBITORS
PROTIVIRUSNE UČINKOVINE PROTI HCV: ZAVIRALCI PROTEAZNE HCV
HCV ANTIVIRALS
PROTIVIRUSNA ZDRAVILA PROTI HCV
HCV geno/subtype and presence of baseline Q80K polymorphism in HCV genotype 1a
HCV geno/podtip in prisotnost polimorfizma Q80K ob izhodišču pri HCV genotipa 1
HCV geno/subtype and presence of baseline Q80K polymorphism in HCV genotype 1a
HCV geno/podtip in prisotnost polimorfizma Q80K ob izhodišču pri HCV genotipa 1a
HCV geno/subtype and presence of Q80K polymorphism in HCV genotype 1a
HCV geno/podtip in prisotnost polimorfizma Q80K HCV genotipa 1a
HCV geno/subtype and presence of Q80K polymorphism in HCV genotype 1a
HCV geno/podtip in prisotnost polimorfizma Q80K ob izhodišču pri HCV genotipa 1
HCV genotype
genotip HCV
HCV Genotype 1b Exviera and ombitasvir/paritaprevir/ritonavir
HCV Genotip 1b Exviera in ombitasvir/paritaprevir/ritonavir
HCV genotype and baseline virus load are prognostic factors which are known to affect response rates.
virusna obremenitev na začetku zdravljenja sta znana prognostične dejavnika, ki vplivata na pogostnost odziva.
HCV GT 1 or 4
GT 1 ali 4 HCV
HCV GT 3
GT 3 HCV
HCV PRODUCTS
ZDRAVILA ZA ZDRAVLJENJE HCV
HCV protease inhibitor
Zaviralec proteaze HCV
HCV Protease Inhibitors
in inhalirani ali intranazalni
HCV Protease Inhibitors
Inhibitorji proteaze HCV
HCV Protease Inhibitors
koncentracije.
HCV protease inhibitors
Zaviralci proteaze HCV
HCV protease monotherapy
HCV proteazna monoterapija
HCV replicons expressing the sofosbuvir-associated resistance substitution S282T were fully susceptible to other classes of anti-HCV agents.
Replikoni HCV z izraženo substitucijo S282T, povezano z odpornostjo na sofosbuvir, so bili v celoti dovzetni za druge razrede učinkovin proti HCV.
HCV RNA < 25 IU/ml at End of Treatment
Koncentracija HCV RNK < 25 i.e./ml ob koncu zdravljenja
HCV RNA < 25 IU/ml at planned end of HCV treatment, and not achieving SVR12.
< 25 i.e./ml ob načrtovanem zaključku zdravljenja okužbe s HCV, brez doseženega SVR12.
HCV RNA undetectable
HCV RNA nezaznavna
HCV RNA undetectable at 24 weeks after the end of treatment (SVR24) for study AI444010.
HCV RNA, manjša od LLOQ v 12. tednu po koncu zdravljenja (SVR12), v študiji AI444010 pa kot nezaznavna raven HCV RNA v 24. tednu po koncu zdravljenja (SVR24).
HCV RNA values were determined using the Roche TaqMan Assay; a patient’s HCV RNA may vary from visit to visit.
Vrednosti HCV RNA so bile ugotovljene s pomočjo testa Roche TaqMan; vrednost HCV RNA bolnika se lahko med obiski razlikuje.
HCV RNA ≥ 6 million IU/mL
HCV RNA ≥ 6 milijonov i.e./ml
HCV Treatment- experienced*
HCV, predhodno zdravljenje
HCV Treatment- naïve
HCV, brez predhodnega zdravljenja
HCV-RNA levels should be monitored at Treatment Weeks 8, 12, and 24, and for other time points as clinically indicated.
Vrednosti HCV-RNA je treba spremljati v 8., 12. in 24. tednu zdravljenja in v drugih časovnih obdobjih, kot je klinično primerno.
HCV-RNA negative
Negativen izvid testa na HCV- RNA
HCV-RNA negative
Negativna
HCV-RNA negative or
HCV-RNA ali
HCV-RNA negative or
Negativen izvid testa na HCV- RNA
HCV-RNA negative or
Negativen izvid testa na HCV-RNA
HCV-RNA negative or
Negativna
HCV/HBV (Hepatitis B Virus) co-infection
Sočasna okužba s HCV in HBV (virusom hepatitisa B)
HCV/HBV (Hepatitis B Virus) co-infection
Sočasna okužba s HCV/HBV (virusom hepatitisa B)
HCV/HBV (hepatitis B virus) co-infection
Sočasna okužba z virusom HCV in virusom HBV (virus hepatitisa B)
HCV/HIV co-infected adults – ERADICATE
Odrasli s sočasno okužbo HCV/HIV – ERADICATE
HCV/HIV co-infected adults – ION-4
Odrasli s sočasno okužbo HCV/HIV – ION 4
HCV/HIV co-infected patients - PHOTON-1 (study 123)
Bolniki s sočasno okužbo z virusoma HCV in HIV – PHOTON-1 (študija 123)
HCV/HIV co-infected patients receiving peginterferon alfa-2b/ribavirin treatment and cART may be at increased risk to develop haematological abnormalities (as neutropenia, thrombocytopenia and anaemia) compared to HCV mono-infected patients.
Bolniki, ki so sočasno okuženi z virusom HCV in HIV ter se zdravijo s peginterferonom alfa- 2b/ribavirinom in s terapijo cART, imajo lahko povečano tveganje za nastanek hematoloških motenj (v obliki nevtropenije, trombocitopenije in anemije) v primerjavi s tistimi, ki so okuženi samo s HCV.
HCV/HIV co-infected patients receiving peginterferon alfa-2b/ribavirin treatment and HAART may be at increased risk to develop haematological abnormalities (as neutropenia, thrombocytopenia and anaemia) compared to HCV mono-infected patients.
Bolniki, ki so sočasno okuženi s HCV/HIV ter se zdravijo s peginterferonom alfa-2b/ribavirinom in s terapijo HAART, imajo lahko povečano tveganje za nastanek hematoloških motenj (v obliki nevtropenije, trombocitopenije in anemije) v primerjavi s tistimi, ki so okuženi samo s HCV.
HCV/HIV co-infected patients receiving peginterferon alfa-2b/ribavirin treatment and HAART may be at increased risk to develop haematological abnormalities (as neutropenia, thrombocytopenia and anaemia) compared to HCV mono-infected patients.
Bolniki, ki so sočasno okuženi z virusom HCV in HIV ter se zdravijo s peginterferonom alfa- 2b/ribavirinom in s terapijo HAART, imajo lahko povečano tveganje za nastanek hematoloških motenj (v obliki nevtropenije, trombocitopenije in anemije) v primerjavi s tistimi, ki so okuženi samo s HCV.
HCV/HIV co-infected patients:
Bolniki, sočasno okuženi s HCV in HIV:
HCV/HIV co-infection
Sočasna okužba z virusoma HCV in HIV
HCV/HIV-1
in s sočasno
HCV/HIV-1 co-infected patients should be treated in the same way as HCV mono-infected patients.
Bolnike s sočasno okužbo s HCV in HIV-1 je treba zdraviti enako kot bolnike, ki so okuženi samo s HCV.
HCV/Human immunodeficiency virus type (HIV)-1 co-infection
Sočasna okužba s HCV/virusom humane imunske pomanjkljivosti-1 (HIV-1)
HCV/Human immunodeficiency virus type 1 (HIV-1) co-infection
Sočasna okužba s HCV/virusom humane imunske pomanjkljivosti-1 (HIV-1)
HD-DEX POM+LD -DEX
VO deks POM+NO deks
HD-DEX POM+LD -DEX
VO-deks POM+NO- deks
HD-DEX POM+LD-DEX
VO-deks POM+NO-deks
HDL cholesterol is often called ‘good’ cholesterol because it helps keep the ‘bad’ cholesterol from building up in the arteries and because it protects against heart disease.
HDL holesterol pogosto imenujemo "dobri" holesterol, ker pomaga preprečevati kopičenje "slabega" holesterola v arterijah in ker varuje pred boleznijo srca.
HDL cholesterol is often called ‘good’ cholesterol because it helps keep the ‘bad’ cholesterol from building up in the arteries and because it protects against heart disease.
Holesterol HDL pogosto imenujemo „dobri“ holesterol, ker pomaga preprečevati kopičenje „slabega“ holesterola v arterijah in ker varuje pred boleznimi srca.
HDL- C (%)
HDL- H (%)
HDL-C
HDL
HDL-C
Lp(a)
HDL-C (%)
HDL- H (%)
HDL-C (%)
HDL-H (%)
HDL-cholesterol, mean % change from baseline
HDL-holesterol, povprečna sprememba v % od izhodišča
HDPE (high density polyethylene) bottles closed with polypropylene screw closures, with a polyethylene faced induction heat seal liner.
Plastenke iz HDPE (polietilena visoke gostote) zaprte s polipropilenskimi pokrovčki z navojem, zapečatene s polietilensko folijo s pomočjo toplotne indukcije.
HDPE (high-density polyethylene) bottles with PP (polypropylene) caps Pack sizes of 100 film-coated tablets.
Plastenke iz HDPE (polietilen visoke gostote) s PP (polipropilenskimi) zaporkami Velikosti pakiranja po 100 filmsko obloženih tablet.
HDPE BOTTLE
HDPE STEKLENICA
HDPE BOTTLE
HPDE STEKLENICA
HDPE BOTTLE
PLASTENKA IZ HDPE
HDPE bottle
Plastenke iz HDPE
HDPE bottle
polietilenska plastenka
HDPE BOTTLE
VSEBNIK IZ HDPE
HDPE bottle closed with a LDPE plug- in adapter and a tamper-proof child resistant closure and a measuring syringe
HDPE-plastenka, zaprta z adapterjem iz LDPE, ki se pritisne v plastenko, in za otroke varno navojno zaporko, ter merilno brizgo
HDPE BOTTLE OUTER CARTON - 25 MG CAPSULES
ŠKATLA ZA PLASTENKO IZ HDPE – 25 mg KAPSULE
HDPE BOTTLE OUTER CARTON - 50 MG CAPSULES
ŠKATLA ZA PLASTENKO IZ HDPE – 50 mg KAPSULE
HDPE BOTTLE OUTER CARTON – 37.5 MG CAPSULES
ŠKATLA ZA PLASTENKO IZ HDPE - 37,5 mg KAPSULE
HDPE bottle pack should be used within 30 days (for 30’s count) and 100 days (for 200’s count) after first opening.
Po prvem odprtju je treba plastenko iz polietilena visoke gostote uporabiti v 30 dneh (pakiranje po 30 kapsul) in 100 dneh (pakiranje po 200 kapsul).
HDPE bottle polypropylene measuring syringe
steklenička iz polietilena visoke, polipropilensko odmerno brizgalko
HDPE bottle with plastic screw cap and a silica gel desiccant.
Plastenka iz polietilena visoke gostote (HDPE) s plastično navojno zaporko in sredstvom za sušenje s silicijevim dioksidom.
HDPE bottle with polypropylene (PP) screw cap closure with induction sealing liner containing 100 tablets.
HDPE plastični vsebnik s polopropilensko (PP) navojno zaporko z indukcijskim pečatom s 100 tabletami.
HDPE bottle with white opaque polypropylene screw cap with aluminium induction sealing liner wad and desiccant.
Je pakirano v HDPE vsebnike z belo poplipropilensko neprozorno navojno zaporko z aluminijastim indukcijskim pečatom in sušilnim sredstvom.
HDPE BOTTLE – 12.5 MG CAPSULES
PLASTENKA IZ HDPE – 12,5 mg KAPSULE
HDPE BOTTLE – 25 MG CAPSULES
PLASTENKA IZ HDPE – 25 mg KAPSULE
HDPE BOTTLE – 37.5 MG CAPSULES
PLASTENKA IZ HDPE – 37,5 mg KAPSULE
HDPE BOTTLE – 50 MG CAPSULES
PLASTENKA IZ HDPE – 50 mg KAPSULE
HDPE bottle.
HDPE steklenice za tablete.
HDPE bottle.
HDPE steklenice.
HDPE bottle: After first opening, use within 120 days.
HDPE vsebnik: Po prem odprtju porabiti v 120 dneh.
HDPE Bottle: This medicinal product does not require any special storage conditions
Plastenka iz HDPE: Za shranjevanje zdravila niso potrebna posebna navodila.
HDPE bottles : 3 years
Plastenke iz polietilena visoke gostote (HDPE): 3 leta
HDPE bottles of 100 film-coated tablets
HDPE plastenke s 100 filmsko obloženimi tabletami
HDPE bottles of 100 film-coated tablets with a PP screw cap.
HDPE steklenica po 100 filmsko obloženih tablet s PP navojno zaporko.
HDPE bottles of 30 film-coated tablets
HDPE plastenke s 30 filmsko obloženimi tabletami
HDPE bottles with a polypropylene cap and a foil induction seal.
Plastenke HDPE s polipropilenskim pokrovom in induktivno zvarjeno zaporko iz folije.
HDPE bottles with child-resistant polypropylene (PP) caps and a silica gel desiccant containing 90 tablets.
HDPE plastenke s polipropilenskimi (PP) zaporkami s sistemom zapiranja, varnim pred otroci, in s sušilnim sredstvom iz silikagela, ki vsebujejo 90 tablet.
HDPE bottles with plastic closure with induction inner seal.
Steklenice iz HDPE s plastično zaporko z zaščitno folijo.
HDPE bottles with plastic closure with induction innerseal.
Steklenice iz HDPE s plastično zaporko z zaščitno folijo.
HDPE bottles with polypropylene closures or child resistant polypropylene closures and silica gel desiccant containing 30 or 100 tablets.
HDPE steklenicah z zaporkami iz polipropilena ali za otroke varnimi zaporkami iz polipropilena ter sušilnim sredstvom, silika gel, ki vsebujejo 30 ali 100 tablet.
HDPE bottles: 3 years Blisters: 2 years
Plastenke HDPE: 3 leta Pretisni omoti: 2 leti
HDPE bottles: 5 years
Plastenke iz polietilena visoke gostote (HDPE): 5 let
HDPE container with LDPE lid and desiccant Pack sizes: 30 or 250 tablets.
Vsebnik iz HDPE s pokrovčkom iz LDPE in sušilom Velikosti pakiranj: 30 ali 250 tablet
HDPE container with PP screw cap packed in carton.
Vsebnik HDPE s PP navojnim pokrovčkom v škatli.
HDPE containers: 2 years.
HDPE vsebniki: 2 leti.
HDPE containers: Do not store above 30°C. Blisters: Do not store above 25°C.
HDPE vsebniki: Shranjujte pri temperaturi do 30°C. Pretisni omoti: Shranjujte pri temperaturi do 25°C.
HDPE plastic bottle
Plastenka po
HDPE tablet container with LDPE lid:
Vsebnik za tablete iz HDPE s pokrovčkom iz LDPE:
HDPE tablet containers with polypropylene screw caps with desiccant insert containing 30, 60, 100 or 175 film-coated tablets.
Vsebniki za tablete HDPE, s polipropilenskimi navojnimi pokrovčki s sušilom, v katerih je po 30, 60, 100 ali 175 filmsko obloženih tablet.
HDPE vials (125 doses)
HDPE viale (125 odmerkov)
HDPE vials (25 or 50 doses)
HDPE viale (25 ali 50 odmerkov)
he becomes pregnant or thinks for any reason that she may be pregnant,
če zanosi ali iz kakršnegakoli razloga domneva, da je noseča,
He may advise you to stop applying this medicine for a few days (i.e. to have a short rest from treatment).
Morda vam bo priporočil, da prekinete uporabo tega zdravila za nekaj dni (t.j. kratko prekinitev zdravljenja).
he misses her expected menstrual period,
če ji izostane pričakovana menstruacija,
He or she may do a urine check to make sure the change in colour is not hiding other problems.
Opravil bo preiskavo urina in se prepričal, da sprememba barve ne prikriva drugih težav.
He or she may suggest a switch to an alternative Levitra formulation with a different dose, depending on how well it works for you.
Lahko vam bo predlagal zamenjavo z drugo obliko ali jakost zdravila Levitra, odvisno od tega kako zdravilo Levitra učinkuje pri vas.
He or she may suggest a switch to an alternative vardenafil formulation with a different dose, depending on how well it works for you.
Lahko vam bo predlagal zamenjavo z drugo obliko ali jakost vardenafila, odvisno od tega kako zdravilo Vivanza učinkuje pri vas.
He or she may suggest a switch to an alternative vardenafil formulation with a different dose, depending on how well it works for you.
Lahko vam bo predlagal zamenjavo z drugo obliko ali jakostjo vardenafila, odvisno od tega kako zdravilo Vivanza učinkuje pri vas.
He or she may suggest a switch to an alternative Vivanza formulation with a different dose, depending on how well it works for you.
Lahko vam bo predlagal zamenjavo z drugo obliko ali jakost zdravila Vivanza, odvisno od tega kako zdravilo Vivanza učinkuje pri vas.
He or she might adjust the dose according to your needs.
Morda bo moral odmerek prilagoditi vašim potrebam.
He or she will decide if Pandemic influenza vaccine H5N1 MedImmune is suitable for you.
Presodil bo, ali je Cepivo proti pandemski gripi H5N1 MedImmune primerno za vas.
He or she will decide whether to decrease the infusion rate or to stop the infusion completely.
Odločil se bo za upočasnitev hitrosti infundiranja ali za ustavitev infundiranja.
He or she will decide whether to slow down the infusion rate or whether to stop the infusion completely.
Odločil se bo, ali naj hitrost infundiranja upočasni ali infundiranje povsem ustavi.
he stops using contraception unless she commits to not having sexual intercourse (abstinence), she needs to change contraception.
če preneha uporabljati kontracepcijo, razen če se vnaprej odpove spolnim odnosom,
he/she has a close contact such as a household member who has a weakened immune system, e.g., a person with cancer or who is taking medicines that may weaken the immune system.
je otrok v tesnem stiku z družinskim članom, ki ima oslabljen imunski sistem, npr. z bolnikom z rakom ali bolnikom, ki jemlje zdravila, ki bi lahko oslabila imunski sistem;
he/she has any disorder of the gastrointestinal system.
ima otrok kakršnekoli težave s prebavili;
he/she has not been gaining weight and growing as expected. he/she has any disease or is taking any medicine which reduces his/her resistance to infection.
e telesna masa otroka ali rast ne povečujeta v skladu s pričakovanji; ima otrok katerokoli bolezen ali jemlje katerokoli zdravilo, ki zmanjšuje njegovo odpornost na okužbe.
He/she may decide if your dose should be adjusted.
Odločil, se boali je vaš odmerek potrebno prilagoditi.
He/she may suggest you switch to a different dose of this medicine.
Morda vam bo predlagal drugačen odmerek zdravila.
He/she will decide whether you should be given Visudyne.
Zdravnik bo odločil, ali je primerno, da dobite zdravilo Visudyne ali ne.
He/she will determine whether to monitor your treatment or whether it is necessary for you to stop using Raptiva.
Zdravnik bo določil ali nadzorovati vaše zdravljenje ali pa je potrebno da prenehate z uporabo zdravila Raptiva.
He/she will determine whether to stop using Raptiva or continue treatment with closer observation.
Zdravnik bo določil ali prekiniti z uporabo zdravila Raptiva ali nadaljevati zdravljenje z bolj tesnim nadzorom.
He/she will work out the correct dose of Retacrit for you to use, how long the treatment should continue and by what route the medicine will be given.
Določil bo pravilni odmerek zdravila Retacrit za vas, kako dolgo bo zdravljenje trajalo in na kakšen način boste zdravilo prejemali.
Head and neck cancer
Adenokarcinom želodca
Head and neck cancer
Rak glave in vratu Zdravilo
Head injury Contusion
poškodba glave kontuzija
Head injury Contusion
poškodbe glave
Headache
(takojšnje
Headache
glavobo l
Headache
glavobol, utrujenost.
Headache
glavobol.
headache
glavobol;
Headache
glavobolom
Headache
glomerulonefritis
Headache
Hipokinezija
headache
höfuðverkur
Headache
izpuščaj
Headache
omotica
Headache
Pogosti
Headache
redki
Headache (14.3%)
Glavobol (14,3 %)
Headache (17.5%) (G3/4: 0.7%)
glavobol (17,5 %) (3./4. stopnje: 0,7 %)
Headache (age 2 to 5 years)
glavobol (starost od 2 do 5 let)
headache (cancer patients)
glavobol (bolniki z rakom)
headache (chronic renal failure patients)
glavobol (bolniki s kronično ledvično okvaro)
headache (especially at the beginning of treatment)
glavobol (zlasti na začetku zdravljenja)
Headache (including migraine), neuropathy (including peripheral neuropathy), dizziness, insomnia
glavobol (vključno z migreno), nevropatija (vključno s periferno nevropatijo), omotica, nespečnost
Headache (including sinus headache, migraine)
Glavobol (vključno s sinusnim glavobolom, migreno)
Headache (including sinus headache, migraine, head discomfort)
glavobol (vključno z sinusnim glavobolom, migreno, neprijetnim občutkom v glavi)
Headache (most common side effect)
glavobol (najpogostejši neželeni učinek)
Headache (N), Restlessness (N)
glavobol (N), nemir (N)
headache (very common in children)
glavobol (zelo pogost pri otrocih)
headache * nausea
glavobolu * slabosti
Headache and a flu-like syndrome consisting of fever, fatigue, weakness, drowsiness, chills and bone, joint and/or muscle ache.
Glavobol in gripi podoben sindrom, ki obsega zvišano telesno temperaturo, utrujenost, šibkost, zaspanost, mrzlico in bolečine v kosteh, sklepih in/ali mišicah.
headache and back pain
glavobol in bolečina v hrbtu,
headache and back pain
glavobol in bolečine v hrbtu,
Headache and diarrhoea have been reported shortly after starting filgrastim therapy, typically in less than 10 % of patients.
Pri manj kot 10 % bolnikov sta se kmalu po začetku terapije s filgrastimom pojavila glavobol in diareja.
Headache and dizziness
glavobol in omotičnost
Headache and insomnia
Glavobol in nespečnost
Headache and muscular pain.
Glavobol in bolečine v mišicah.
Headache Asthenia
občasni glavobol občasni astenija
headache bruises in the upper and lower leg muscle due to the injections.
glavobol podplutbe na mišicah zgornjega in spodnjega dela nog zaradi injiciranja.
Headache Common
glavobol pogosti
headache common cold
glavobol, prehlad.
Headache Dizziness
glavobol omotica
Headache Dizziness
glavobol vrtoglavica
Headache Dizziness
glavobol, omotica
Headache Dizziness Dysgeusia
glavobol omotica disgevzija
Headache Dizziness Dysgeusia Paraesthesia Burning sensation Hyperaesthesia Hypoaesthesia
glavobol omotica disgevzija parestezija pekoč občutek hiperestezija hipoestezija
Headache Dizziness Lethargy Somnolence
glavobol omotica letargija zaspanost tremor parestezija
Headache Dizziness Lethargy Somnolence Tremor Paraesthesia
glavobol omotica letargija zaspanost tremor parestezija
Headache Dizziness Tremor
glavobol omotica tremor
Headache Dysgeusia
glavobol dizgevzija
Headache Encephalopathy Convulsion Cerebral haemorrhage Memory impairment Paresis
glavobol encefalopatija konvulzije možganska krvavitev motnje spomina pareza
headache excessive sweating
glavobol prekomerno znojenje
Headache Fatigue
glavobol utrujenost
Headache Fatigue
odpoved srca
Headache Fatigue
utrujenost
headache feeling sick (nausea)
glavobol, slabost v želodcu (navzea).
headache feeling sick (nausea).
glavobol občutek slabosti (navzea).
headache feeling sick (nausea).
glavobol, občutek slabosti (navzea).
headache feeling tired
glavobol občutek utrujenosti
headache fever
glavobol povišana telesna temperatura
headache frequent urination
glavobol pogosto uriniranje
Headache has occurred with INCRELEX treatment.
Pri zdravljenju z zdravilom INCRELEX so poročali o glavobolu.
Headache in adults
glavobol pri odraslih
Headache including migraine
Glavobol vključno z migreno
Headache including migraine
glavobol, vključno z migreno
headache infusion-related reactions
glavobol; reakcije, povezane z infuzijo.
Headache Insomnia
glavobol nespečnost
Headache is one of the most frequent events reported with a positive timeline.
Glavobol je eden izmed najpogostejših dogodkov, kjer so poročali o pozitivni vzročni povezavi med začetkom jemanja zdravila in pojavom neţelenega učinka.
headache local reactions at the injection site such as pain, itching, bruising, swelling or irritation.
glavobol lokalne reakcije na mestu injiciranja, kot so bolečina, srbenje, modrica, oteklina ali razdraženost.
headache nasal discharge.
glavobol izcedek iz nosu
Headache Nervous system disorders [Not Elsewhere Classified]
glavobol, bolezni živčevja [nerazvrščene drugje]
headache or back pain
glavobol ali bolečina v hrbtu;
headache or dizziness
glavobol ali omotica
Headache or drowsiness
glavobol ali dremavost
Headache or feeling tired.
glavobol ali občutek utrujenosti,
headache or migraine
glavobol ali migrena
headache or sleepiness
glavobol ali zaspanost
headache pain at the injection site
glavobol, bolečina na mestu injiciranja.
Headache Paraesthesia Dysgeusia Burning sensation
glavobol, parestezija, disgevzija, pekoč občutek
headache sexual difficulties
glavobol, motnje spolnosti.
Headache Somnolence
glavobol zaspanost
Headache Somnolence
glavobol, zaspanost
Headache Somnolence Tremor Syncope Seizures
epileptični napadi
Headache Tremor
glavobol tremor
Headache Tremor Dysgeusia
glavobol tremor disgevzija
headache tummy pain (abdominal pain).
glavobol, bolečine v trebuhu.
headache upper abdominal pain (from your chest to the belly button)
glavobol, bolečina v zgornjem delu trebuha (med prsnim košem in popkom).
headache vascular access thrombosis (blood clots in your dialysis access).
glavobol, tromboza žilnega pristopa (strdki krvi v vašem dializnem pristopu).
Headache was reported by 27% of subjects who received Rapiscan in clinical trials.
O glavobolu so poročali pri 27% osebah, ki so v kliničnih preskušanjih prejele zdravilo Rapiscan.
Headache was the most common in GIST patients.
Glavobol je bil najpogostejši pri bolnikih z GIST.
Headache was the most common in GIST patients.
Pri bolnikih z GIST je bil najpogostejši glavobol.
Headache was the most commonly reported adverse reaction.
Najpogostejši neželeni učinek, o katerem so poročali, je bil glavobol.
headache weakness
glavobol oslabelost
headache with a stiff neck or back
glavobol z otrdelim vratom ali hrbtom;
Headache 
glavobol 
headache*
glavobol
headache*
glavobol*,
headache* , insomnia*
glavobol* , nespečnost*;
Headache* Dizziness*
glavobol* vrtoglavica
Headache*, dizziness*
glavobol*, omotica
headache,
glavobol
headache,
glavobol,
headache,
utrujenost,
headache, a feeling of “spinning” even when you are standing still (vertigo)
glavobol, občutek “vrtenja”, tudi če stojite pri miru (vrtoglavica),
Headache, abdominal pain, diarrhoea and nausea are among those adverse reactions that have been most commonly reported in clinical trials (and also from post-marketing use).
Med neželenimi učinki, ki so bili v kliničnih preskušanjih (in tudi med uporabo zdravila po prihodu na trg) opisani najpogosteje, so glavobol, bolečine v trebuhu, driska in navzea.
Headache, abdominal pain, indigestion, feeling sick, dry eyes, nasal dryness.
Glavobol, bolečine v trebuhu, prebavne motnje, slabo počutje, suhe oči, suha nosna sluznica.